SCHEMBL13017481

SCHEMBL13017481

Cc1ccc2nc(C)c(-c3ccccc3)nc2c1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.83
ALDH1A1 P00352 4/20 0.83
L3MBTL1 Q9Y468 2/20 0.83
NQO2 P16083 1/20 0.60
TDP1 Q9NUW8 1/20 0.59
PSMB5 P28074 1/20 0.56
MAPT P10636 4/20 0.53
RAB9A P51151 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
LMNA P02545 2/20 0.53
KMT2A Q03164 1/20 0.51
ATM Q13315 1/20 0.51
TLR9 Q9NR96 1/20 0.51
DHODH Q02127 1/20 0.49
HPGD P15428 3/20 0.47
GAA P10253 2/20 0.47
NPC1 O15118 2/20 0.47
PDE10A Q9Y233 1/20 0.47
POLB P06746 1/20 0.46
CASP3 P42574 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16687605 1.00 KDM4E (0.83) KDM4EALDH1A1L3MBTL1NQO2TDP1
SCHEMBL18082998 0.97 KDM4E (0.77) KDM4EALDH1A1L3MBTL1NQO2TDP1
SCHEMBL31415566 0.91 KDM4E (1.00) KDM4EALDH1A1L3MBTL1NQO2TDP1
SCHEMBL31070213 0.91 KDM4E (1.00) KDM4EALDH1A1L3MBTL1NQO2TDP1
SCHEMBL31070206 0.91 KDM4E (1.00) KDM4EALDH1A1L3MBTL1NQO2TDP1
SCHEMBL1104817 0.91 KDM4E (1.00) KDM4EALDH1A1L3MBTL1NQO2TDP1
SCHEMBL825060 0.89 KDM4E (0.96) KDM4EALDH1A1L3MBTL1NQO2TDP1
SCHEMBL18082983 0.89 KDM4E (0.65) KDM4EALDH1A1L3MBTL1NQO2TDP1
SCHEMBL12553477 0.89 KDM4E (0.96) KDM4EALDH1A1L3MBTL1NQO2TDP1
SCHEMBL18082999 0.88 KDM4E (0.64) KDM4EALDH1A1L3MBTL1NQO2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434701-B2 Aminoquinoxaline derivatives for treatment of neurodegenerative diseases CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2016-09-06 US disclosed
EP-1501907-B1 SOLUTION-PROCESSABLE PHOSPHORESCENT MATERIALS CAMBRIDGE ENTPR LTD (GB) 2016-07-27 EP disclosed
US-9023978-B2 Solution-processable phosphorescent materials CAMBRIDGE ENTERPRISE LTD. (GB) 2015-05-05 US disclosed
US-9023978-B2 Solution-processable phosphorescent materials CAMBRIDGE ENTERPRISE LTD. (GB) 2015-05-05 US disclosed
EP-2264123-A2 Solution-processable phosphorescent materials Cambridge Display Technology Limited (GB) 2010-12-22 EP disclosed